Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.75 million versus the consensus estimate of $15.1 million.

Cash, cash equivalents and short-term bank deposits were approximately $28.6 million at June 30, 2022.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.